|Slideshows|May 18, 2017

7 Medical Illnesses That May Present as Anxiety

Author(s)Yu Dong, MD, PhD, Fatima Noorani, MD, Rushi Vyas, MD

Beyond psychosocial implications of anxiety disorders, an array of physiological effects may ensue.

To view a PDF, of this slideshow, click here.

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Subscribe Now!

Latest CME

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Video

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Video

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Video

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

In-Person Event

Southern California Psychiatry Conference

July 10-11, 2026

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

In-Person Event

Jersey City Psychiatry

October 2-3, 2026

In-Person Event

Southern Florida Psychiatry Conference

December 4-5, 2026

Video

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Video

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

7 Medical Illnesses That May Present as Anxiety

Newsletter

Related Content

Fasedienol for Social Anxiety Disorder Does Not Demonstrate Significant Improvement in Phase 3 Study

Psychedelic PSX-001 for Generalized Anxiety Disorder: A Conversation With Lou Barbato, MD

Placebo Response Rates Vary Across Psychiatric Disorders

Study Finds Semaglutide Is Associated With Improved Cognitive Function in Individuals With Psychiatric Disorders

LSD for Generalized Anxiety Disorder: New Findings Review With Maurizio Fava, MD

Latest CME

Real Psychiatry 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Optimizing Care for Patients With Tardive Dyskinesia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Southern California Psychiatry Conference

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Jersey City Psychiatry

Southern Florida Psychiatry Conference

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Trending on Psychiatric Times

CAPS: A New Program to Support Early Intervention in Patients at Risk for Suicide

2025 Schizophrenia Insights: Ending the Year With Positive Data

Don't Let the Lights Go Out: Be Like Ahmed al Ahmed

Trontinemab Shows Promise for Treatment of Alzheimer Disease in New Data at CTAD

Chatbot Privacy Is an Oxymoron: Assume Your Data Is Always At Risk